- Palisade Bio (PALI) stock is up alongside new drug data.
- The company saw positive performance from PALI-2108 as an ulcerative colitis treatment.
Palisade Bio (NASDAQ:PALI) stock is climbing higher on Tuesday after the clinical-stage biopharmaceutical company revealed additional data for its ulcerative colitis (UC) treatment.
The big news here is Palisade Bio completing its analysis of ex-vivo bioactivation of PALI-2108. That includes the successful conversion of PALI-2108 into its active PDE4 inhibitor form.
Palisade Bio notes that PALI-2108 was able to do this in stool samples of both healthy patients and those with UC. It did so at a mean rate of 90.1% with conversion “increasing over time.”
https://investorplace.com/2024/04/why-is-palisade-bio-pali-stock-up-57-today/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.